Cystatins (CST2, CST3, CST5), key inhibitors of cysteine proteases, were also decreased, potentially contributing to increased proteolytic activity and stromal degradation—an established pathogenic mechanism in keratoconus [43–45]. The gene discussed is CST5; the disease is keratoconus.